Daily Sepsis Research Analysis
Three impactful sepsis studies stood out today: a mechanistic paper identifies an endothelial CCL7–CCR1–KAT2A–STAT1 succinylation pathway that drives macrophage polarization and septic acute lung injury; a Mendelian randomization study implicates impaired LDL-C clearance (PCSK9/ApoB/ApoE variants) in higher septic shock mortality; and a multicenter double-blind RCT shows low-dose hydrocortisone does not improve 28-day survival in cirrhotic septic shock.
Summary
Three impactful sepsis studies stood out today: a mechanistic paper identifies an endothelial CCL7–CCR1–KAT2A–STAT1 succinylation pathway that drives macrophage polarization and septic acute lung injury; a Mendelian randomization study implicates impaired LDL-C clearance (PCSK9/ApoB/ApoE variants) in higher septic shock mortality; and a multicenter double-blind RCT shows low-dose hydrocortisone does not improve 28-day survival in cirrhotic septic shock.
Research Themes
- Endothelial-immune crosstalk and metabolic epigenetics in septic lung injury
- Host lipid metabolism (LDL receptor pathway) as a causal determinant of septic shock outcomes
- Therapeutic refinement in cirrhosis-associated septic shock (steroids show no survival benefit)
Selected Articles
1. Endothelial-Derived CCL7 Promotes Macrophage Polarization and Aggravates Septic Acute Lung Injury via CCR1-Mediated STAT1 Succinylation.
Endothelial CCL7 drives CCR1+ macrophage metabolic reprogramming and M1 polarization via KAT2A-dependent STAT1 succinylation, amplifying inflammation in septic ALI. Endothelial-specific CCL7 inhibition reduced lung injury severity in sepsis models, nominating the CCL7–CCR1–KAT2A–STAT1 axis as a therapeutic target.
Impact: This study reveals an epigenetic-metabolic mechanism linking endothelial chemokine signaling to macrophage polarization and lung injury, identifying druggable nodes (CCR1, KAT2A, STAT1 succinylation).
Clinical Implications: CCR1 antagonists or strategies to modulate endothelial CCL7 release and STAT1 succinylation could attenuate inflammatory lung injury in sepsis, informing target selection for translational studies.
Key Findings
- Endothelial cells secrete CCL7 that induces metabolic reprogramming and M1 polarization of CCR1+ macrophages.
- Endothelial-specific inhibition of CCL7 reduces the severity of septic acute lung injury in vivo.
- CCL7–CCR1 signaling increases KAT2A expression, enhancing STAT1 succinylation and binding to promoters of glycolytic genes to drive inflammatory cascades.
Methodological Strengths
- Multi-level mechanistic dissection linking chemokine signaling to epigenetic modification and metabolism
- In vivo validation with endothelial-specific inhibition and genetic models
Limitations
- Preclinical murine models without human clinical validation
- Abstract truncation limits details on knockout phenotypes and breadth of experimental systems
Future Directions: Test CCR1 antagonists or KAT2A/STAT1-succinylation modulators in sepsis ALI models and evaluate endothelial CCL7/CCR1 signatures in human cohorts to enable biomarker-guided trials.
Acute lung injury (ALI) is a significant complication of sepsis, wherein the interaction between pulmonary vascular endothelial cells and immune cells plays a pivotal role in the pathogenesis. In this study, it is demonstrated that secretion of chemokine C-C motif ligand 7 (CCL7) by endothelial cells (ECs) induces metabolic reprogramming and M1 polarization of C-C motif chemokine receptor 1-positive (CCR1⁺) macrophages. It is noteworthy that mice with specific inhibition of endothelial-derived CCL7 exhibit reduced severity of septic ALI, underscoring the critical role of CCL7 in the progression of sepsis. Mechanistically, activation of the CCL7-CCR1 axis enhances STAT1 succinylation through upregulation of KAT2A expression, leading to increased STAT1 binding to the promoter of glycolytic genes in macrophages. This epigenetic regulation modulates metabolic reprogramming and M1 polarization of macrophages, thereby driving inflammatory cascades in septic ALI. Furthermore, in sepsis models, Ccr1-knockout (Ccr1
2. Decreased Clearance of Low-Density Lipoprotein Cholesterol is Causally Associated With Increased Mortality of Septic Shock.
Genetically higher pre-infection LDL-C, reflecting reduced LDL receptor–mediated clearance, causally increases 28-day mortality in septic shock. PCSK9 and apolipoprotein (ApoB, ApoE) variants underlie this risk, whereas HMGCR variants do not confer benefit, suggesting that enhancing LDL-C clearance—not reducing production—may improve outcomes.
Impact: Provides causal human genetic evidence linking LDL receptor pathway function to septic shock mortality and differentiates clearance versus production mechanisms, directly informing therapeutic targeting (e.g., PCSK9 inhibition).
Clinical Implications: Supports clinical trials of PCSK9 pathway modulation to enhance LDL receptor–mediated clearance of lipid toxins. Emphasizes that statin-like production reduction may not improve septic shock survival.
Key Findings
- Predicted pre-infection LDL-C was substantially higher than measured LDL-C at septic shock onset (141 vs 40 mg/dL; p<0.001).
- Higher genetically predicted pre-infection LDL-C causally increased 28-day mortality (HR 2.78; p=0.039) in septic shock.
- PCSK9 variants (↑LDLR clearance) were associated with decreased mortality (p=0.003), whereas HMGCR variants (↓production) showed no benefit and opposite effect (p=0.039); ApoB and ApoE variants drove the association.
Methodological Strengths
- Two-sample Mendelian randomization leveraging >150,000-participant GWAS for causal inference
- Multicenter ICU cohort with genotyping and targeted pathway analysis (PCSK9, HMGCR, ApoB, ApoE)
Limitations
- MR assumptions (e.g., no pleiotropy) and population specificity (Japanese cohorts) may limit generalizability
- Clinical intervention effects (e.g., actual PCSK9 inhibitor use) were not tested
Future Directions: Randomized trials testing PCSK9 inhibition or other LDLR-enhancing strategies in septic shock; validation across ancestries and integration with lipidome/pathogen lipid toxin profiling.
OBJECTIVE: To determine whether low-density lipoprotein cholesterol (LDL-C) levels, set by the balance of clearance and production, causally contribute to septic shock 28-day mortality. DESIGN: We measured LDL-C levels and genotypes in patients with septic shock. Using Genotyping and Genome-Wide Association Study summary statistics from over 150,000 Japanese participants, we genetically predicted pre-infection LDL-C levels. Two-sample Mendelian randomization was used to assess the causal relationship between predicted pre-infection LDL-C levels and 28-day mortality. We analyzed PCSK9 and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) genotypes to determine if LDL-C clearance or production was the underlying mechanism. SETTING: Multicenter ICUs in Japan. PATIENTS: Genotyped septic shock patients ( n = 614). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Predicted pre-infection LDL-C levels were much higher than directly measured LDL-C levels at the onset of septic shock (141 mg/dL vs. 40 mg/dL, p < 0.001). Two-sample Mendelian randomization revealed that high predicted pre-infection LDL-C levels were causally associated with increased septic shock 28-day mortality (hazard ratio, 2.78; p = 0.039). PCSK9 genetic variants that increase LDL-C clearance via the LDL receptor (genetically proxied PCSK9 inhibitor treatment) were associated with decreased mortality ( p = 0.003) while HMGCR genetic variants that decrease LDL-C production (genetically proxied statin treatment) were not associated with decreased septic shock mortality (indeed the opposite effect was observed, p = 0.039). The two main genetic variants driving the association between high predicted pre-infection LDL-C levels and increased mortality were in apolipoprotein genes ( ApoB100 -rs13306206 and ApoE -rs7412), apolipoproteins involved in LDL-C binding to the LDL receptor. CONCLUSIONS: Low LDL-C clearance explains the causal association between high genetically predicted pre-infection LDL-C levels and increased septic shock mortality. PCSK9 , ApoB , and ApoE variants were identified as causal, all related to the LDL receptor or its interaction with LDL-C. Enhancing LDL receptor-mediated clearance of pathogen lipid toxins may improve septic shock outcomes.
3. Low-Dose Hydrocortisone in Cirrhotic Patients With Septic Shock: A Double-Blind Randomised Placebo-Controlled Trial.
In cirrhotic septic shock, low-dose hydrocortisone did not reduce 28-day mortality or accelerate shock resolution compared with placebo, while dysglycemia was more frequent with steroids. Inadequate empiric antibiotics and ACLF severity predicted mortality, underscoring antimicrobial optimization.
Impact: Provides randomized evidence in a high-risk subgroup, suggesting routine hydrocortisone use may not confer survival benefit and highlighting the paramount role of appropriate antibiotics.
Clinical Implications: Avoid routine low-dose hydrocortisone in cirrhotic septic shock requiring low-to-moderate vasopressors; ensure early, adequate empiric antibiotics and consider careful glucose monitoring if steroids are used.
Key Findings
- No difference in 28-day mortality between hydrocortisone and placebo (35% vs 39.5%; p=0.84).
- Shock resolution rates and time to resolution were similar; refractory shock deaths were more frequent with placebo.
- Dysglycemia (hypo-/hyperglycemia) occurred more often with hydrocortisone; inadequate empiric antibiotic therapy (HR 6.40) and ACLF severity predicted mortality.
Methodological Strengths
- Double-blind, multicenter randomized placebo-controlled design
- Prespecified clinical endpoints with stratified cirrhotic population
Limitations
- Early termination with small sample size (n=83) limits power to detect modest effects
- Most patients required only low-to-moderate vasopressor doses, limiting generalizability to severe shock
Future Directions: Larger pragmatic RCTs in cirrhotic septic shock with stratification by vasopressor dose and adrenal function; trials prioritizing early adequate antibiotics and evaluating steroid-sparing strategies.
BACKGROUND AND AIMS: Steroid supplementation remains controversial in septic shock, partly due to the heterogeneity of the populations studied. Cirrhotic patients with sepsis frequently develop relative adrenal insufficiency, showing poor response to vasopressors and poor prognosis. Early administration of low-dose hydrocortisone might facilitate shock reversal and reduce mortality in this population. METHODS: Double-blind, randomised, placebo-controlled multicentre trial, enrolling adult cirrhotic patients with septic shock. Patients were assigned to receive i.v. hydrocortisone (100 mg followed by a continuous infusion of 200 mg/24 h) or placebo, for at least 3 days, followed by a tapering period of 3-7 days, depending on the time of shock resolution. Primary endpoint was 28-day all-cause mortality. RESULTS: After enrolment of 83 patients the trial was stopped early due to slow inclusions. Most patients required low-to-moderate doses of vasopressors. There was no difference in 28-day mortality (35% vs. 39.5%; p = 0.84) between hydrocortisone and placebo groups. Shock resolution (85% vs. 72.1%; p = 0.25) and days to shock resolution [3 days (2.2-4; IQR) vs. 4 (2-7.5; IQR)] were also similar between groups. More patients receiving placebo died of refractory shock (47.6% vs. 8.7%). No significant differences between treatment arms were observed in shock relapse, new shock episodes or bacterial or fungal superinfections during hospital stay. Hypo- and hyperglycaemias were more frequent in the hydrocortisone arm. Severity of ACLF at inclusion and inadequacy of empirical antibiotic therapy (HR = 6.40; 95% CI: 3.21-12.79) independently predicted 28-day mortality. CONCLUSIONS: Supplemental hydrocortisone did not improve short-term survival in cirrhotic patients with septic shock requiring low-to-moderate doses of vasopressors. TRIAL REGISTRATION: S-number University Hospitals Leuven, Belgium: S55168; EUDRACT: 2010-024273-38; Clinicaltrials.gov id: NCT02602210.